Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial

NCT05564403 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05564403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05564403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 9, 2024
Completion date
October 1, 2026
Enrollment
66 (estimated)
Sites
207

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract carcinoma, advanced gallbladder carcinoma, advanced intrahepatic cholangiocarcinoma, recurrent biliary tract carcinoma, recurrent gallbladder carcinoma, recurrent intrahepatic cholangiocarcinoma, stage iii distal bile duct cancer ajcc v8, stage iii gallbladder cancer ajcc v8, stage iii hilar cholangiocarcinoma ajcc v8, stage iii intrahepatic cholangiocarcinoma ajcc v8, stage iv distal bile duct cancer ajcc v8, stage iv gallbladder cancer ajcc v8, stage iv hilar cholangiocarcinoma ajcc v8, stage iv intrahepatic cholangiocarcinoma ajcc v8, unresectable biliary tract carcinoma, unresectable gallbladder carcinoma, unresectable intrahepatic cholangiocarcinoma